Geron Corporation (GERN), a commercial-stage biopharmaceutical company, announced that President, Chief Executive Officer and Chairman John Scarlett will depart from the company on March 31, 2025.
While a search for a new Chief Executive Officer with significant commercial experience is underway, the Board of Directors has appointed Board member Dawn Carter Bir as Interim President and Chief Executive Officer, effective immediately.
Additionally, Elizabeth O'Farrell has been appointed as Chair of the Board.
"It has been an honor to serve Geron over the last 14 years and participate in the development and launch of our first-in-class telomerase inhibitor," said Dr. Scarlett. "I am deeply grateful to have had the opportunity to build and lead an outstanding team and see the positive impact of imetelstat on patients. I look forward to the future success of the company."
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.